Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)

NCT02951598 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02951598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02951598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Lead sponsor
Eli Lilly and Company
Phase
Observational
Overall status
Active, not recruiting
Start date
October 29, 2016
Completion date
April 28, 2026
Enrollment
1,400 (estimated)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, mild cognitive impairment